Laymen’s summary:
The response to the antipsychotic drug clozapine varies among individuals, with tobacco smoking being a known factor. This study investigated the impact of genetic variations in CYP1A and NFIB genes on clozapine evels in smokers and non-smokers. The results showed that patients with these genetic variants had lower clozapine concentrations, regardless of smoking status. Smokers with the variants had even lower levels compared to non-smokers without the variants. These findings suggest that genotyping for these genetic variations could guide clozapine dosing and improve treatment outcomes for patients with treatment-resistant schizophrenia, particularly smokers.
Access the publication here.